Uncertainty Surrounds Medicare's Coverage Costs for Obesity Drugs
While Medicare will offer Wegovy and Zepbound at a low monthly fee for older adults, the total cost implications for taxpayers remain undisclosed.
Editorial Staff
1 min read
Updated 9 days ago
Starting in July 2026, older adults on Medicare will have access to obesity drugs Wegovy and Zepbound for a monthly fee of $50. This initiative aims to support those struggling with obesity.
However, the financial implications of this coverage for taxpayers are still unclear, as Medicare has not provided information on the total costs associated with these drugs.
The lack of transparency raises questions about the overall impact on healthcare spending and the sustainability of such programs.